Xuemeng He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xuemeng He has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Huan Lian
National Institutes for Food and Drug Control (NIFDC), No. 31, Huatuo Road, Daxing District, Beijing 102629, China
1 shared publication - Liang Chen
National Institutes for Food and Drug Control (NIFDC), No. 31, Huatuo Road, Daxing District, Beijing 102629, China
1 shared publication - Menghang Guo
National Institutes for Food and Drug Control (NIFDC), No. 31, Huatuo Road, Daxing District, Beijing 102629, China
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (8) , 764
Mesenchymal Stem Cell Exosomes in Combination with Hydrogels for Osteoarthritis: From Exploratory Applications to Optimization and Translational Outlook
Osteoarthritis (OA) is a chronic degenerative joint disorder characterized primarily by cartilage degradation and extensive inflammation. Its pathological progression is closely associated with the dysregulation of critical signaling pathways; consequently, the therapeutic targets of these pathways have become crucial for intervening underlying mechanisms of cartilage damage. Extensive laboratory studies have found that mesenchymal stem cell-derived exosomes (MSC-Exos) can deliver bioactive cargoes such as microRNAs (miRNAs) and antioxidant enzymes to modulate these targets, thereby exerting therapeutic effects that include mitigating inflammation, inhibiting chondrocyte apoptosis, maintaining extracellular matrix homeostasis, and promoting tissue repair. However, the clinical translation of MSC-Exos is significantly hampered by inherent limitations, including source variability, low stability, and rapid clearance from the joint cavity. Hydrogels, recognized for their excellent biocompatibility, three-dimensional biomimetic architecture, and controlled drug release capabilities, have been used for OA therapy. Therefore, this review summarizes current research on the combined application of exosomes and hydrogels for OA treatment, and proposes optimization strategies for exosome preconditioning, hydrogel material selection, and hydrogel functional design. These strategies aim to enhance exosome functionality as well as enable sustained responsive, and localized exosome release within the joint, thereby improving the therapeutic efficacy for OA.
- 27 July 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (8) , 764
Open AccessMesenchymal Stem Cell Exosomes in Combination with Hydrogels for Osteoarthritis: From Exploratory Applications to Optimization and Translational Outlook
Osteoarthritis (OA) is a chronic degenerative joint disorder characterized primarily by cartilage degradation and extensive inflammation. Its pathological progression is closely associated with the dysregulation of critical signaling pathways; consequently, the therapeutic targets of these pathways have become crucial for intervening underlying mechanisms of cartilage damage. Extensive laboratory studies have found that mesenchymal stem cell-derived exosomes (MSC-Exos) can deliver bioactive cargoes such as microRNAs (miRNAs) and antioxidant enzymes to modulate these targets, thereby exerting therapeutic effects that include mitigating inflammation, inhibiting chondrocyte apoptosis, maintaining extracellular matrix homeostasis, and promoting tissue repair. However, the clinical translation of MSC-Exos is significantly hampered by inherent limitations, including source variability, low stability, and rapid clearance from the joint cavity. Hydrogels, recognized for their excellent biocompatibility, three-dimensional biomimetic architecture, and controlled drug release capabilities, have been used for OA therapy. Therefore, this review summarizes current research on the combined application of exosomes and hydrogels for OA treatment, and proposes optimization strategies for exosome preconditioning, hydrogel material selection, and hydrogel functional design. These strategies aim to enhance exosome functionality as well as enable sustained responsive, and localized exosome release within the joint, thereby improving the therapeutic efficacy for OA.